ZA879615B - Quinoline compound - Google Patents

Quinoline compound

Info

Publication number
ZA879615B
ZA879615B ZA879615A ZA879615A ZA879615B ZA 879615 B ZA879615 B ZA 879615B ZA 879615 A ZA879615 A ZA 879615A ZA 879615 A ZA879615 A ZA 879615A ZA 879615 B ZA879615 B ZA 879615B
Authority
ZA
South Africa
Prior art keywords
quinoline compound
compound
quinoline
concerned
chem
Prior art date
Application number
ZA879615A
Other languages
English (en)
Inventor
Arthur Page Phillips
Page Phillips Arthur
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA879615B publication Critical patent/ZA879615B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Secondary Cells (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
ZA879615A 1986-12-23 1987-12-22 Quinoline compound ZA879615B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868630702A GB8630702D0 (en) 1986-12-23 1986-12-23 Quinoline compound

Publications (1)

Publication Number Publication Date
ZA879615B true ZA879615B (en) 1989-08-30

Family

ID=10609475

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA879615A ZA879615B (en) 1986-12-23 1987-12-22 Quinoline compound

Country Status (22)

Country Link
US (1) US4937248A (da)
EP (1) EP0272910B1 (da)
JP (1) JPS63166866A (da)
KR (1) KR880007514A (da)
AT (1) ATE65993T1 (da)
AU (1) AU594220B2 (da)
CA (1) CA1318671C (da)
DE (1) DE3772015D1 (da)
DK (1) DK163429C (da)
ES (1) ES2029842T3 (da)
FI (1) FI90768C (da)
GB (1) GB8630702D0 (da)
GR (1) GR3002445T3 (da)
HU (1) HU196991B (da)
IE (1) IE60619B1 (da)
IL (1) IL84917A (da)
MX (1) MX9203788A (da)
MY (1) MY102277A (da)
NZ (1) NZ223036A (da)
PH (1) PH23448A (da)
PT (1) PT86448B (da)
ZA (1) ZA879615B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166160A (en) * 1986-12-23 1992-11-24 Burroughs Wellcome Co. Quinoline compound
GB8820174D0 (en) * 1988-08-25 1988-09-28 Wellcome Found Quinoline compound
IL134662A0 (en) * 1997-09-24 2001-04-30 Orion Corp Bisethers of 1-oxa, aza and thianaphthalen-2- ones as phospholamban inhibitors
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU6941200A (en) 1999-08-27 2001-03-26 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
WO2001016139A1 (en) 1999-08-27 2001-03-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CO5200852A1 (es) 1999-09-14 2002-09-27 Lilly Co Eli Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1838956A (zh) 2003-08-22 2006-09-27 配体药物公司 作为雄激素受体调节剂化合物的6－环氨基－2－喹啉酮衍生物
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616855A (en) * 1948-01-15 1952-11-04 Procter & Gamble Detergent composition
US4329347A (en) * 1978-02-17 1982-05-11 Boehringer Ingelheim Gmbh Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril
JPS5777676A (en) * 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
NZ212209A (en) * 1984-05-29 1988-08-30 Pfizer Quinolone derivatives and pharmaceutical compositions
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
US4845100A (en) * 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
FR2580646A1 (fr) * 1985-04-19 1986-10-24 Synthelabo Derives de 2(1h)-quinolinone, leur preparation et leur application en therapeutique
GB8529362D0 (en) * 1985-11-28 1986-01-02 Pfizer Ltd Quinolone cardiac stimulants
DK111387A (da) * 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US4886809A (en) * 1986-07-31 1989-12-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof

Also Published As

Publication number Publication date
DK680887D0 (da) 1987-12-22
US4937248A (en) 1990-06-26
ES2029842T3 (es) 1992-10-01
IE873490L (en) 1988-06-23
HUT45984A (en) 1988-09-28
GB8630702D0 (en) 1987-02-04
IE60619B1 (en) 1994-07-27
DK680887A (da) 1988-06-24
PH23448A (en) 1989-08-07
AU594220B2 (en) 1990-03-01
GR3002445T3 (en) 1992-12-30
FI875666A0 (fi) 1987-12-22
ATE65993T1 (de) 1991-08-15
PT86448B (pt) 1990-11-20
FI90768C (fi) 1994-03-25
FI90768B (fi) 1993-12-15
PT86448A (en) 1988-01-01
EP0272910B1 (en) 1991-08-07
IL84917A (en) 1991-08-16
MY102277A (en) 1992-05-15
DK163429B (da) 1992-03-02
AU8293387A (en) 1988-06-23
EP0272910A1 (en) 1988-06-29
NZ223036A (en) 1990-11-27
DK163429C (da) 1992-07-20
MX9203788A (es) 1992-07-01
CA1318671C (en) 1993-06-01
HU196991B (en) 1989-02-28
KR880007514A (ko) 1988-08-27
JPS63166866A (ja) 1988-07-11
IL84917A0 (en) 1988-06-30
DE3772015D1 (de) 1991-09-12
FI875666A (fi) 1988-06-24

Similar Documents

Publication Publication Date Title
PT86448A (en) Quinoline compound
IL148516A (en) Retroviral protease inhibiting compound
FI852974A0 (fi) Nya n-hydroxylgruppen skyddande grupper och framstaellningsfoerfarande foer 3-acylamino-1-hydroxi-2-azetidinoner.
DK43882A (da) Fremgangsmaade til fremstilling af cephemforbindelser
GR3004139T3 (da)
TW232013B (da)
ATE50559T1 (de) Substituierte p,p'-methylen-bis-aniline.
FI861506A (fi) Foerfarande foer framstaellning av 1,2-ditiolan-3-pentansyra (tioktsyra).
GR3007460T3 (da)
GB8820174D0 (en) Quinoline compound
EP0171147A3 (en) Anti-diabetic compounds
FI842112A0 (fi) Foerfarande foer framstaellning av- karbolin-3-karboxylsyraderivat.
GR3005734T3 (da)
AU566243B2 (en) Optically active imidazolylpropanols